Juxtapid (lomitapide) is an innovative lipid-lowering drug. As a microsomal triglyceride transfer protein inhibitor, it is specifically indicated for the treatment of specific types of hypercholesterolemia.

What Are the Indications of Juxtapid (Lomitapide)?

Primary Target Population for Treatment

The primary indication of lomitapide is for patients with homozygous familial hypercholesterolemia (HoFH).

This is a rare and severe genetic disorder, in which patients have significantly elevated low-density lipoprotein cholesterol (LDL-C) levels, and traditional lipid-lowering treatments have limited efficacy.

Application Conditions and Limitations

This drug must be used in combination with a low-fat diet and other lipid-lowering therapies.

These therapies include LDL apheresis (when available), aiming to effectively reduce patients' levels of low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol.

Precautions for Use

It is important to note that the efficacy of lomitapide has not been established in non-HoFH patients.

The drug’s impact on the incidence and mortality of cardiovascular diseases has not been determined, which is a key aspect requiring ongoing attention in clinical use.

Specifications and Properties of Juxtapid (Lomitapide)

Capsule Specification Classification

5 mg capsules: Orange/orange two-tone hard gelatin capsules, imprinted with "A733" and "5 mg" in black ink.

10 mg capsules: Orange/white two-tone hard gelatin capsules, imprinted with "A733" and "10 mg" in black ink.

20 mg capsules: White/white two-tone hard gelatin capsules, imprinted with "A733" and "20 mg" in black ink.

Description of Physical Properties

All capsule specifications use hard gelatin capsule shells, containing lomitapide mesylate as the active ingredient.

Packaging Specifications

Capsules of each specification are supplied in bottles of 28 capsules, facilitating long-term medication management for patients.

Storage and Preservation Requirements for Juxtapid (Lomitapide)

Temperature Control Standards

Lomitapide should be stored at a standard room temperature of 20°C to 25°C (68°F to 77°F).

Short-term storage within the range of 15°C to 30°C (59°F to 86°F) is permitted.

Humidity Protection Measures

The drug must be stored in a tightly closed container to strictly prevent moisture intrusion.

Special Handling Requirements

During daily use, ensure that the capsules remain dry.

If exposed to environments with relatively high temperatures (up to 40°C), the mean kinetic temperature must be controlled to not exceed 25°C (77°F), and such exposure should be minimized as much as possible.